{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:46:48Z","timestamp":1784288808074,"version":"3.55.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Survival is generally poor for Chinese patients with advanced melanoma because of high rates of acral and mucosal melanoma and limited therapeutic options. The first analysis of the phase 1b KEYNOTE-151 study showed second-line pembrolizumab was well tolerated and had clinically meaningful antitumor activity in Chinese patients with advanced melanoma. Three-year follow-up is presented. Eligible patients were of Chinese descent and had unresectable stage III\/IV melanoma that progressed after first-line therapy. Patients received pembrolizumab 2 mg\/kg every 3 weeks for \u226435 cycles. Primary end points were safety and objective response rate (ORR). Secondary end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Response was assessed per RECIST v1.1 by blinded independent central review. Subgroup analyses were conducted by melanoma subtype and <jats:italic>BRAF<\/jats:italic> and PD-L1 status (acral melanoma only). 103 patients were enrolled; median follow-up duration (time from first dose to data cutoff [July 13, 2020]) was 44.6 months (IQR, 39.1\u201346.2). Any-grade treatment-related adverse events (TRAEs) occurred in 85.4% of patients, and grade 3\/4 TRAEs in 12.6%. No grade 5 TRAEs occurred. Three patients discontinued pembrolizumab because of TRAEs (immune-mediated hepatitis, pneumonia, and arthritis). Immune-mediated AEs and infusion reactions occurred in 34.0% (grade 3\/4, 2.9%). ORR was 17.6% (95% CI, 10.8\u201326.4; 1 complete response\/17 partial responses), and median DOR was 13.8 months (range, 2.7\u201337.4+). Median PFS was 2.8 months (95% CI, 2.7\u20133.5) and 36-month PFS rate was 5.0%. Median OS was 13.2 months (95% CI, 10.4\u201316.5) and 36-month OS rate was 22.3%. Median OS for patients with known melanoma subtype was 14.8 months for acral, 13.5 months for nonacral cutaneous, and 7.4 months for mucosal melanoma. Among the acral subgroup, median OS was 22.8 months for PD-L1\u2013positive disease, 8.4 months for PD-L1\u2013negative disease, 18.5 months for <jats:italic>BRAF<\/jats:italic> wild-type disease, and 5.8 months for <jats:italic>BRAF<\/jats:italic>-mutant disease. Over 3 years\u2019 follow-up, second-line pembrolizumab continued to show manageable safety, clinically meaningful antitumor activity, and durable responses in Chinese patients with advanced melanoma. Subgroup analysis suggested particular benefit in PD-L1\u2013positive and <jats:italic>BRAF<\/jats:italic> wild-type acral melanoma, although small subgroup sizes preclude definitive conclusions.<\/jats:p><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:uri>https:\/\/clinicaltrials.gov<\/jats:uri>, identifier NCT02821000.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.882471","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T11:32:25Z","timestamp":1665487945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study"],"prefix":"10.3389","volume":"13","author":[{"given":"Lu","family":"Si","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Diede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuizhen","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.32764","article-title":"Burden of melanoma in China, 1990-2017: Findings from the 2017 global burden of disease study","volume":"147","author":"Wu","year":"2020","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.680407","article-title":"Immunotherapy in acral and mucosal melanoma: Current status and future directions","volume":"12","author":"Mao","year":"2021","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2019.04.02","article-title":"Chinese Guidelines for diagnosis and treatment of melanoma 2018 (English version)","volume":"31","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/ij9.0000000000000076","article-title":"Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study","volume":"4","author":"Cui","year":"2019","journal-title":"IJS Oncol"},{"key":"B6","volume-title":"Keytruda\u00ae (pembrolizumab) is the first anti-PD-1 therapy approved in China for advanced melanoma","year":"2018"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: First global approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151)","volume":"12","author":"Si","year":"2019","journal-title":"Transl Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.010","article-title":"Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma","volume":"144","author":"Robert","year":"2021","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-3922","article-title":"Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6454989","article-title":"Factors influencing the efficacy of anti-PD-1 therapy in Chinese patients with advanced melanoma","volume":"2019","author":"Zhao","year":"2019","journal-title":"J Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-1989-8","article-title":"The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series","volume":"66","author":"Wen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2110","article-title":"Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma","volume":"8","author":"Fujisawa","year":"2019","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3237-x","article-title":"Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)","volume":"79","author":"Yamazaki","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/cas.14015","article-title":"Long-term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma","volume":"110","author":"Yamazaki","year":"2019","journal-title":"Cancer Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"abstr 9516","DOI":"10.1200\/JCO.2018.36.15_suppl.9516","article-title":"5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001","volume":"36","author":"Hamid","year":"2018","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.882471\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T11:32:28Z","timestamp":1665487948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.882471\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":17,"alternative-id":["10.3389\/fimmu.2022.882471"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.882471","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]},"article-number":"882471"}}